Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: Induction of remission by the monoclonal antibody Trastuzumab [2]

Annals of Oncology

Volumn 10, Issue 11, 1999, Pages 1393-1394

  Kollmannsberger, C ^a   Pressler, H ^a   Mayer, F ^a   Kanz, L ^a   Bokemeyer, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; CANCER REGRESSION; CANCER RESISTANCE; CASE REPORT; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; LETTER; LUNG METASTASIS; MALE; ONCOGENE NEU; ORCHIECTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032804613     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008365216323     Document Type: Letter

References (3)

1. Bokemeyer C. Kollmannsberger C. Harstrick A. Treatment of patients with cisplatin refractory testicular germ-cell cancer Int J Cancer 1999
2. Henley J. Einhorn L.H. C-erbB-2 (Her-2-neu) overexpression in recurrent germ-cell tumors Proc Am Soc Clin Oncol 18 1999 341a
3. Klapper L.N. Vaisman N. Hurwitz E. A subclass of tumor-inhibitory monoclonal antibodies to Erb2/HER2 blocks crosstalk with growth factor receptor Oncogene 14 1997 2099 2109